WALTHAM, Mass.--(BUSINESS WIRE)--Oscient Pharmaceuticals Corporation (Nasdaq: OSCI) today announced preliminary revenue results for the first quarter ended March 31, 2008. For the first quarter of 2008, the Company expects to record total revenues of approximately $18.5 million, with more than two-thirds derived from sales of ANTARA® (fenofibrate) capsules. The Company expects its total cash, including restricted cash and cash equivalents, as of March 31, 2008, to be approximately $42 million.
